216 related articles for article (PubMed ID: 30554119)
1. Cabazitaxel and silibinin co-encapsulated cationic liposomes for CD44 targeted delivery: A new insight into nanomedicine based combinational chemotherapy for prostate cancer.
Mahira S; Kommineni N; Husain GM; Khan W
Biomed Pharmacother; 2019 Feb; 110():803-817. PubMed ID: 30554119
[TBL] [Abstract][Full Text] [Related]
2. CD44 targeted chemotherapy for co-eradication of breast cancer stem cells and cancer cells using polymeric nanoparticles of salinomycin and paclitaxel.
Muntimadugu E; Kumar R; Saladi S; Rafeeqi TA; Khan W
Colloids Surf B Biointerfaces; 2016 Jul; 143():532-546. PubMed ID: 27045981
[TBL] [Abstract][Full Text] [Related]
3. Pancreatic cancer stem cell proliferation is strongly inhibited by diethyldithiocarbamate-copper complex loaded into hyaluronic acid decorated liposomes.
Marengo A; Forciniti S; Dando I; Dalla Pozza E; Stella B; Tsapis N; Yagoubi N; Fanelli G; Fattal E; Heeschen C; Palmieri M; Arpicco S
Biochim Biophys Acta Gen Subj; 2019 Jan; 1863(1):61-72. PubMed ID: 30267751
[TBL] [Abstract][Full Text] [Related]
4. Redox-sensitive and hyaluronic acid functionalized liposomes for cytoplasmic drug delivery to osteosarcoma in animal models.
Chi Y; Yin X; Sun K; Feng S; Liu J; Chen D; Guo C; Wu Z
J Control Release; 2017 Sep; 261():113-125. PubMed ID: 28666726
[TBL] [Abstract][Full Text] [Related]
5. The synergistic anticancer effect of salinomycin combined with cabazitaxel in CD44+ prostate cancer cells by downregulating wnt, NF-κB and AKT signaling.
Erdogan S; Serttas R; Turkekul K; Dibirdik I
Mol Biol Rep; 2022 Jun; 49(6):4873-4884. PubMed ID: 35705771
[TBL] [Abstract][Full Text] [Related]
6. Nanoplatform Assembled from a CD44-Targeted Prodrug and Smart Liposomes for Dual Targeting of Tumor Microenvironment and Cancer Cells.
Lv Y; Xu C; Zhao X; Lin C; Yang X; Xin X; Zhang L; Qin C; Han X; Yang L; He W; Yin L
ACS Nano; 2018 Feb; 12(2):1519-1536. PubMed ID: 29350904
[TBL] [Abstract][Full Text] [Related]
7. Nanohybrid magnetic liposome functionalized with hyaluronic acid for enhanced cellular uptake and near-infrared-triggered drug release.
Nguyen VD; Zheng S; Han J; Le VH; Park JO; Park S
Colloids Surf B Biointerfaces; 2017 Jun; 154():104-114. PubMed ID: 28329728
[TBL] [Abstract][Full Text] [Related]
8. Combination Therapy of Metastatic Castration-Recurrent Prostate Cancer: Hyaluronic Acid Decorated, Cabazitaxel-Prodrug and Orlistat Co-Loaded Nano-System.
Qu Z; Ren Y; Shen H; Wang H; Shi L; Tong D
Drug Des Devel Ther; 2021; 15():3605-3616. PubMed ID: 34447241
[TBL] [Abstract][Full Text] [Related]
9. Targeted nanomedicine for prostate cancer therapy: docetaxel and curcumin co-encapsulated lipid-polymer hybrid nanoparticles for the enhanced anti-tumor activity in vitro and in vivo.
Yan J; Wang Y; Zhang X; Liu S; Tian C; Wang H
Drug Deliv; 2016 Jun; 23(5):1757-62. PubMed ID: 26203689
[TBL] [Abstract][Full Text] [Related]
10. Hyaluronic Acid Surface Modified Liposomes Prepared via Orthogonal Aminoxy Coupling: Synthesis of Nontoxic Aminoxylipids Based on Symmetrically α-Branched Fatty Acids, Preparation of Liposomes by Microfluidic Mixing, and Targeting to Cancer Cells Expressing CD44.
Bartheldyová E; Effenberg R; Mašek J; Procházka L; Knötigová PT; Kulich P; Hubatka F; Velínská K; Zelníčková J; Zouharová D; Fojtíková M; Hrebík D; Plevka P; Mikulík R; Miller AD; Macaulay S; Zyka D; Drož L; Raška M; Ledvina M; Turánek J
Bioconjug Chem; 2018 Jul; 29(7):2343-2356. PubMed ID: 29898364
[TBL] [Abstract][Full Text] [Related]
11. Hyaluronic acid-decorated liposomal nanoparticles for targeted delivery of 5-fluorouracil into HT-29 colorectal cancer cells.
Mansoori B; Mohammadi A; Abedi-Gaballu F; Abbaspour S; Ghasabi M; Yekta R; Shirjang S; Dehghan G; Hamblin MR; Baradaran B
J Cell Physiol; 2020 Oct; 235(10):6817-6830. PubMed ID: 31989649
[TBL] [Abstract][Full Text] [Related]
12. Overcoming drug-resistant lung cancer by paclitaxel-loaded hyaluronic acid-coated liposomes targeted to mitochondria.
Tian Y; Zhang H; Qin Y; Li D; Liu Y; Wang H; Gan L
Drug Dev Ind Pharm; 2018 Dec; 44(12):2071-2082. PubMed ID: 30112929
[TBL] [Abstract][Full Text] [Related]
13. A novel double-targeted nondrug delivery system for targeting cancer stem cells.
Qiao S; Zhao Y; Geng S; Li Y; Hou X; Liu Y; Lin FH; Yao L; Tian W
Int J Nanomedicine; 2016; 11():6667-6678. PubMed ID: 27994463
[TBL] [Abstract][Full Text] [Related]
14. Hyaluronic acid-modified DOTAP/DOPE liposomes for the targeted delivery of anti-telomerase siRNA to CD44-expressing lung cancer cells.
Taetz S; Bochot A; Surace C; Arpicco S; Renoir JM; Schaefer UF; Marsaud V; Kerdine-Roemer S; Lehr CM; Fattal E
Oligonucleotides; 2009 Jun; 19(2):103-16. PubMed ID: 19374532
[TBL] [Abstract][Full Text] [Related]
15. Silibinin, A Natural Blend In Polytherapy Formulation For Targeting Cd44v6 Expressing Colon Cancer Stem Cells.
Patel S; Waghela B; Shah K; Vaidya F; Mirza S; Patel S; Pathak C; Rawal R
Sci Rep; 2018 Nov; 8(1):16985. PubMed ID: 30451890
[TBL] [Abstract][Full Text] [Related]
16. Hyaluronic acid modified pH-sensitive liposomes for targeted intracellular delivery of doxorubicin.
Paliwal SR; Paliwal R; Agrawal GP; Vyas SP
J Liposome Res; 2016 Dec; 26(4):276-87. PubMed ID: 26784587
[TBL] [Abstract][Full Text] [Related]
17. Targeted and controlled drug delivery system loading artersunate for effective chemotherapy on CD44 overexpressing cancer cells.
Tran TH; Nguyen TD; Van Nguyen H; Nguyen HT; Kim JO; Yong CS; Nguyen CN
Arch Pharm Res; 2016 May; 39(5):687-94. PubMed ID: 27015824
[TBL] [Abstract][Full Text] [Related]
18. Hyaluronic acid-nimesulide conjugates as anticancer drugs against CD44-overexpressing HT-29 colorectal cancer in vitro and in vivo.
Jian YS; Chen CW; Lin CA; Yu HP; Lin HY; Liao MY; Wu SH; Lin YF; Lai PS
Int J Nanomedicine; 2017; 12():2315-2333. PubMed ID: 28392690
[TBL] [Abstract][Full Text] [Related]
19. Synergistic Enhancement of Cellular Uptake With CD44-Expressing Malignant Pleural Mesothelioma by Combining Cationic Liposome and Hyaluronic Acid-Lipid Conjugate.
Sakurai Y; Kato A; Hida Y; Hamada J; Maishi N; Hida K; Harashima H
J Pharm Sci; 2019 Oct; 108(10):3218-3224. PubMed ID: 31229434
[TBL] [Abstract][Full Text] [Related]
20. CD44 targeted delivery of siRNA by using HA-decorated nanotechnologies for KRAS silencing in cancer treatment.
Tirella A; Kloc-Muniak K; Good L; Ridden J; Ashford M; Puri S; Tirelli N
Int J Pharm; 2019 Apr; 561():114-123. PubMed ID: 30822503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
